Aquestive Therapeutics Announces FDA Clearance of Investigational New Drug Application (IND) for AQST-109 Epinephrine Oral Film
WARREN, N.J., Feb. 24, 2022 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical…
WARREN, N.J., Feb. 24, 2022 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical…
Aiming to strengthen uninterruptible-power-supply business in North America TOKYO–(BUSINESS WIRE)–Mitsubishi Electric Corporation (TOKYO: 6503) announced…
Company working to accelerate lead clinical programs; expects multiple clinical readouts in 2022 WESTPORT, Conn.,…
Recent independent Data Safety Monitoring Board (DSMB) review recommended the INTEGRIS-IPF Phase 2a trial continue…
Mesoblast Prepares for Resubmission of Biologics License Application Late-Stage Clinical Pipeline Late-Stage Clinical Pipeline NEW…
JSP191 is well tolerated with no treatment-related severe adverse events in 17 subjects with myelodysplastic…
CAMBRIDGE, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) — Vericel Corporation (NASDAQ:VCEL), a leader in advanced…
MALVERN, Pa., Feb. 24, 2022 (GLOBE NEWSWIRE) — Baudax Bio, Inc. (the “Company” or “Baudax…
Montrouge, France, February 24, 2022 DBV Technologies to Report Full Year 2021 Financial Results and…
NEW YORK, Feb. 24, 2022 (GLOBE NEWSWIRE) — Cellectis (Euronext Growth: ALCLS – Nasdaq: CLLS),…
SAN CARLOS, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) — Atreca, Inc. (Atreca) (NASDAQ: BCEL), a…
Well-capitalized with $375.1 million at the end of 2021, funding planned operations into 2024 CAMBRIDGE,…
Company begins 2022 with multiple active programs with data readouts expected this year Initial data…
Phase 1/2 trial of CDK9 inhibitor KB-0742 continues to enroll patients in the dose escalation…
Record Annual Total Revenue of $104.8M, Representing Eighth Consecutive Year of Revenue Growth Company Guides…
Announced RLY-4008 interim clinical data that suggest it is the first investigational therapy that selectively…
– Significant progress made increasing global patient access to sotrovimab; approximately 1.7 million doses sold to…
Expanded pipeline with recently licensed targeted interventional radiotherapeutics platform Announced positive interim data from ReSPECT-GBM…
– Patient enrollment continues in KOMET-001 Phase 1b study of ziftomenib (KO-539) in AML –…
Safety-critical multicore 6U solutions accelerate data-intensive sensor processing applications while lowering risk Mercury’s new BuiltSAFE…